Researchers suggest that future studies could explore NRF2 activity inhibitors applicable to humans or develop inhibitors targeting succinated GPX4 to induce ferroptosis in hereditary leiomyomatosis and renal cell cancer cells. This evidence concerns the gene GPX4 and hereditary leiomyomatosis and renal cell cancer.